Phase 2B, Partially Blinded, Randomized Study in Treatment Naive HCV [hepatitis C virus] G1 to Compare the Efficacy, Safety, and Tolerability of Three Doses of Locteron [interferon alpha-2b] Plus Ribavirin Given Bi-Weekly in Comparison With PEG-Intron [peginterferon-alfa-2B] Plus Ribavirin Given Weekly.

Trial Profile

Phase 2B, Partially Blinded, Randomized Study in Treatment Naive HCV [hepatitis C virus] G1 to Compare the Efficacy, Safety, and Tolerability of Three Doses of Locteron [interferon alpha-2b] Plus Ribavirin Given Bi-Weekly in Comparison With PEG-Intron [peginterferon-alfa-2B] Plus Ribavirin Given Weekly.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms EMPOWER; SELECT-2
  • Sponsors Biolex
  • Most Recent Events

    • 28 Jun 2012 Planned number of patients changed from 100 to 108 as reported by European Clinical Trials Database.
    • 10 May 2011 Results of a preliminary analysis of the sustained virological response rates presented at the Digestive Disease Week 2011.
    • 04 Apr 2011 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top